CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
在 CAR-T 太空竞赛中咬一口 BiTE
英文原题：Taking a BiTE out of the CAR T space race.
查看英文原题
Taking a BiTE out of the CAR T space race.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法以指数速度发展，并通过新一代 CAR 和扩展至浆细胞疾病的适应证，力求革新 CAR-T 治疗领域。双特异性 T 细胞衔接器（BiTE）疗法近期的进展可能缩小其与 CAR-T 的差距；BiTE 可提供现货或按需治疗等关键优势，且毒性特征可管理，使更广泛的患者能够在门诊接受治疗。两种治疗形式并存对整体治疗管理仍十分重要，也将加速细胞疗法和 BiTE 的下一轮迭代。本文总结两类疗法治疗血液系统恶性肿瘤的当前进展、潜在未来方向及其对医疗系统的经济影响。
展开英文摘要原文
Chimaeric antigen receptor T-cell (CAR T) therapy has evolved at an exponential pace and seeks to revolutionize the CAR T space with next-generation CARs and expanding indications in plasma cell dyscrasias. Recent developments in Bispecific T-cell engager therapy (BiTEs) may level the playing field with CAR T therapy, offering key advantages with off-the-shelf or on-demand treatment and a manageable toxicity profile to encompass a wider pool of eligible patients in the outpatient setting.
The coexistence of both modalities will remain important in overall management and accelerate the next iteration of both cellular and BiTEs. This article summarises the current progress, potential future of both therapies for haematologic malignancies, and their economic implications on the healthcare system.
论文信息
- 作者
- Patel A、Oluwole O、Savani B、Dholaria B
- 单位
- Department of Hematology and Bone Marrow Transplant, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.United States
- 期刊
- British journal of haematology2021 Dec
- 原文标识
- PubMed 34131894 · DOI 10.1111/bjh.17622